Clinical Trial Update: A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia [Phase 2]

View source ↗

Summary

Phase 2 trial assessing oral LPCN 1148 for efficacy, safety, and tolerability in male subjects with liver cirrhosis and sarcopenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Cirrhosis
• Sarcopenia

Drugs mentioned

• LPCN 1148

Snippet

Sponsor: Lipocine Inc. | Conditions: Liver Cirrhosis, Sarcopenia | Phase 2 | Status: COMPLETED